B of A Securities Maintains Buy on BridgeBio Pharma, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham has reiterated a Buy rating for BridgeBio Pharma (NASDAQ:BBIO) and maintained a price target of $42.
September 11, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities has reiterated its Buy rating for BridgeBio Pharma, maintaining a price target of $42, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $42 price target by B of A Securities suggests a positive outlook for BridgeBio Pharma. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100